Exchange: NASDAQ·Updated 07:46 PM EST
VTGN logo

VTGN VistaGen Therapeutics Inc

$0.1636
$0.023
(12.33%)
Today
Closed $0.1636
$0.003
(1.83%)
After Hours
Reported EarningsNov 13
Mkt Cap$7.56M
Vol919,933.00

About VTGN

Vistagen Therapeutics, Inc. is a late clinical-stage biopharmaceutical company, which engages in developing and commercializing medication and treatment for anxiety, depression, and other central nervous system disorders. Its product portfolio includes Fasedienol (PH94B) nasal spray for social anxiety disorder, Itruvone (PH10) nasal spray for depression disorders, AV-101 oral NMDR glycine site antagonist for depression and neurological disorders, PH15 acute treatment for improvement of cognition, PH80 acute management of vasomotor symptoms due to menopause, and PH284 acute management of Wasting syndrome (Cachexia). The company was founded by H. Ralph Snodgrass and Gordon Keller on May 26, 1998 and is headquartered in South San Francisco, CA.
60

Bullish Sentiment

How do you feel about VTGN?

BluntForceOptions
Following up on the afternoon buying... pressed our entries today across a basket of small-cap biotechs we own right around these multi-month low levels - $VTGN $EYPT $NMRA $TNXP $VYGR - When the macro tape de-risks indiscriminately into a sector washout like this, pipeline values and cash per share get completely detached from reality. We took out the trash and pruned the dead weight in the portfolio earlier this month specifically for days like today. With our short index hedges locking down the downside into the weekend, we can afford to stay patient and add to these dislocations on our terms. Unplug and enjoy the weekend.
14
BluntForceOptions
$VTGN breaking out of its multi-week base after carving out a solid floor. Are y'all paying attention yet?
1
7
defineme44
$VTGN VTGN FDA Update: Vistagen planned to meet with the FDA by September 30 regarding fasedienol's next Phase 3 trial. The FDA generally provides official meeting minutes within 30 days, placing October 29–30 in the expected window if the meeting occurred at quarter-end. Vistagen is not required to publicly release those results within 30 days. Management could already have feedback and be evaluating its next steps. Favorable FDA support for one additional Phase 3 trial would be a significant potential catalyst, but the meeting outcome remains unconfirmed.
12
joe77w
$VTGN so maybe out news next week. I cannot believe its trading for less than 20 cents or 9 mln market cap, a fraction of its SHELL/CASH/PIPELINE cumulative value.
7
BluntForceOptions
$VTGN just dropped Q2 numbers and everything came in right on track. The takeaways: • FDA Clarity: Constructive Type C feedback confirms LSAS as the primary endpoint and expands the next Phase 3 fasedienol plan to cover overall SAD treatment for the general population. • Burn Cut Nearly in Half: R&D dropped from $15.9M to $6.6M YoY, bringing net loss down to $10.7M as management tightens expenses. • Runway: $20.0M in cash and marketable securities carries operations into 2027. Chart setup: On the 1-hour, price has carved out a clean multi-bottom floor at $0.165, reclaimed the 50- and 100-SMAs, and is coiling right beneath the 200-SMA ($0.19) with RSI neutral at 50 and Stochastics curling higher. Added another 30,000 shares to the stack this week... wouldn't be surprised at all to see a solid relief rally kick off through that 200-SMA. As always, just sharing my work here. Please DYOR. NFA. Have a great weekend, everyone.
6
nvntr
$VTGN - Dr. Williamson coming to Board of Directors after failed Phase 3 tests is a good sign, especally with all his prior accomplishments and familiarrity with FDA regarding new drug applications. I doubt that he would have signed on to a sinking ship. Also their signing on GATC, with it's AI successes and access to clinical testing funding sources. This could be in response to or further prep for FDA at meeting already held. Neither party required to disclose details of a meeting that covered confidential mattters. Then there is the current vesting of deferred benefits for current execs, more likely a precursor for merger or aquisition discussuons than a going out of business bankrupcy scenario. It's a frustating wall of silence, but I believe that their are lots of gears turning, not grinding, in the background.
6
defineme44
$VTGN VTGN is prioritizing survival and continued development while reducing its cash burn. The company is preserving all three lead programs, but fasedienol is clearly the immediate priority. Lets see what Monday brings.
1
3
focafoca99
$VTGN briefed on FDA Type C meeting feedback for fasedienol, outlining potential registrational path for social anxiety disorder.
5
StocktwitsEarnings
$VTGN Q2 '27 Earnings Results & Recap • Reported GAAP EPS of -$0.24 up 55.56% YoY • Reported revenue of $0.14M down -46.15% YoY
4
joe77w
$VTGN good news imo, co. understands money funding Is not forever, this is another workforce reduction needed to stay alive the time needed to find a partner to outlicense programs and/or seek a Reverse Merger. FDA news should be positive imo because PR speaks about SAD Phase 3. Current market cap still a fraction of cash position, if good news out 1 usd imo. Lets Hope the coming news with FDA green light for a single ph3 confirmatory study🤞💪 3 valid compounds in ph2/3 should be worth a Little bit, add Shell for RM and cash, instead It seems a defunct co.😐😩
4
Guido1958
$VTGN does not matter. They do not have the money for all the studies unless they get a partner or buyout. What good is it if the FDA approves their drug but they cannot get it to market.🤷‍♂️
3
defineme44
$VTGN FDA UPDATE: Vistagen confirms a productive Type C meeting with the FDA regarding fasedienol's path toward approval for social anxiety disorder. The company is pursuing a new Phase 3 trial using LSAS as the primary endpoint and evaluating whether existing data plus future results could support an NDA. Significant progress after PALISADE-4, but FDA agreement on a single additional trial is not yet confirmed. Financing remains the key hurdle. Now we need the full details from Exhibit 99.1.
3
bo55sab
$VTGN Some stocks make no sense. This had what seems negative news, yet the price has gone up a little and the sentiment has grown alot. What am I missing? BTW I've money invested and do want the SP to go up. So not complaining at all...
3
Guido1958
$VTGN - has anyone noticed thst they pushed back earnings until tomorrow. Only means one thing, they will be filing for bankruptcy and since they report earnings after market close tomorrow, it will drop like a rock. Come Monday, opening price <.05. I was stupid to think this company be successful. After 17 yrs of 0, I now have a great write off to use with my gains other blue chips.
2
Guido1958
$VTGN Tomorrow SS will strong and dance the earnings. He is a master manipulator and Feb 2027 is right around the corner. The only way to get to $1.00 is reverse splits but their cash will be gone. So sad - a lot of individuals lost millions due to gis trickery with words. Bye bye VTGN - another bio bites the dust…📉📉📉📉📉
2
PoseidonCalls
Short sellers are ruining american small caps and driving companies into bankruptcy!! FMFC has barely 800 watchers on Stocktwits and has been shorted down to only 1.5 million market cap. You could literally buy the ENTIRE company! Webull data stating that FMFC has only 492k shares outstanding and 243k shares float. Watch FMFC here. Making a move 🚀 💎 👀 $VTGN $OCGN FL
2
joe77w
$VTGN What Is the worst case scenario here? The best exit would be a Reverse Merger putting at work 15 mln USD plus Shell value worth 7.5 mln plus CVRs for all 3 compounds. A deal like this would provide at least 75 cents imo to shareholders of which .50 to stake in new merged co. CVRs could be a potential goldmine if compounds approved. Just my opinion. Current pps gives no value to SHELL and pipeline and Ip, prices 1/3 net cash or less.
2
THSSKS
$VTGN this could potentially triple if management just sells it. Another bioturd trading at fraction of cash
2
Rayvio_News_Filter
$VTGN 🤝 AmyriAD Therapeutics B.V. acquired the AD04 Alzheimer's disease program and related assets from ADvantage Therapeutics, Inc., adding a Phase 2b-ready neuroinflammation-targeting program to its clinical-stage pipeline. Timely market event
1
Merlintrader
Vistagen $VTGN marked its Phase 3 PALISADE-3 fasedienol trial as completed on the trial registry. The record for social anxiety disorder lists 238 patients enrolled and a completion date of July 13, 2026. Shares closed at $0.17 on Monday, below the SMA50 and below the SMA200, RSI deeply oversold. More details in our hub. Not investment advice.
1

Advertisement|Remove ads.